Discontinued Product(S)-(-)-Atenolol (Cat. No. 0393) has been withdrawn from sale for commercial reasons.
The active enantiomer of (RS)-atenolol, a cardioselective β-adrenergic blocker.
Racemate also available.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Stoschitzky et al (1993) Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies. Chirality 5 15 PMID: 8383518
Merck Index 12 892
View Related Products by Product Action
Keywords: (S)-(-)-Atenolol, (S)-(-)-Atenolol supplier, β1-Adrenergic, α1-Adrenergic, beta1-Adrenergic, b1-adrenergic, Receptors, β1-adrenoceptors, α1-adrenoceptor, beta1-adrenoceptors, b1-adrenoceptors, antagonists, Atenolol, S-Atenolol, Adrenergic, Beta-1, 0393, Tocris Bioscience
Citations for (S)-(-)-Atenolol
Citations are publications that use Tocris products.
Currently there are no citations for (S)-(-)-Atenolol.
Reviews for (S)-(-)-Atenolol
There are currently no reviews for this product. Be the first to review (S)-(-)-Atenolol and earn rewards!
Have you used (S)-(-)-Atenolol?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.